Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...
Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...
When the National Agency for Food and Drugs Administration and Control (NAFDAC) made a burnfire at the Aluu dumpsite near Port ...
The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
Researchers at Indiana University and Wuhan University in China have unveiled a groundbreaking chemical process that could ...
The maker of a new prescription drug product for people with life-threatening allergies is using copayment coupons to build ...
With over 15 years of expertise in developing injectable and liquid pharmaceutical forms, CARBOGEN AMCIS' Saint-Beauzire site ...
The inspection comes after a ProPublica investigation revealed that drugs made at the Glenmark Pharmaceuticals plant ...
Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic ...
Australia trade war has left consumers wondering what this means for them. At least in the short term, it looks like good ...